In June 2026, two Stanford graduates raised $11.6M to build a wearable that reads hormone levels without a needle. Khosla Ventures led the round. A month later, hormone monitoring was the single most active category inside a $120M wave of femtech deals across 17 startups. Neither of those sentences mentions skincare, and that's the point.
Hormonal health platforms pulled in $117.61M across six deals in femtech through June 2026, the second-largest category by capital in the sector. Compare that to hormone-responsive skincare, the beauty industry's answer to the same biological shift: Alloy, the category's most visible brand, has raised $16.3M cumulatively as of July 2025. Six deals in hormone health outpaced an entire skincare subcategory's multi-year fundraising history. That's the gap the headline is pointing at, and it's real, but it's also narrower than it looks.
The money is chasing data, not serums
Clair Health's $11.6M round wasn't for a product you'd find at Sephora. It's a noninvasive wearable hormone monitor, the kind of device that turns a blood draw into a continuous data stream. Investors are betting that hormone levels become something people track the way they track sleep or glucose now, not something they find out about once a year at a doctor's office.
That bet has a market size attached to it. The continuous hormone monitoring market was valued at $325.7 million in 2025 and is projected to reach $716.2 million by 2035, according to market research cited by Forbes. That's a decade to more than double. It's not a beauty-industry-scale number, but it's a specific one, and specificity is what's drawing check writers who spent the last five years watching wearables prove the model in glucose and sleep.
Science&Humans, a hormone health telemedicine company, raised $10M CAD in a Series A that closed in December 2025 and was announced in January 2026. Midi Health, further along, closed a $50M Series C in late 2025 for AI-powered women's health information. Both are clinical and diagnostic plays. Neither sells a cream.
What beauty is actually building, and why it raises less
Hormone-responsive skincare is a real category with real growth. BeautyMatter reports the segment is projected to grow at 15.9% annually from 2025 to 2034, which is a faster clip than most of the beauty industry it sits inside. The problem for founders in this category isn't demand. It's that skincare is a formulation and retail-distribution business, not a diagnostics business, and venture investors price those two things very differently. A monitoring startup sells a platform, recurring data, and a plausible path to acquisition by a health system or insurer. A skincare line sells a product that competes on shelf space against L'Oréal and Estée Lauder, companies that don't need Series A capital to compete. Alloy's $16.3M is not a sign of a failing company. It's a sign that skincare rounds get sized to unit economics and retail margins, not to total addressable data value.
The scale check nobody skips
Here's the number that keeps this honest: the beauty industry is valued at $108.41B in 2026. Global femtech, the entire category hormone health startups sit inside, raised $2.2B in 2024, or 8.5% of total digital health funding. Hormone health's $117.61M in six months of 2026 is a rounding error against beauty's overall size. If the headline claim were about total market value, it would be false on its face.
Ida Tin, the femtech founder credited with coining the term, made the sharper version of this point to Forbes:
"There's literally not a single later-stage venture fund for femtech."That's the honest read of the funding environment. Hormone health is winning early-stage attention and larger individual checks relative to its size, but there's no deep pool of growth capital waiting at Series C and beyond the way there is in, say, enterprise AI or even mainstream beauty. A company that raises a strong seed round in this space still has to find its next check in a market that hasn't built the later-stage infrastructure yet.
There's also a rebranding argument worth taking seriously. Critics could reasonably say that "hormone health" in 2026 is mostly menopause and fertility platforms that existed under other names in 2022, repackaged around a hotter term now that menopause has become culturally visible and destigmatized. Some of that is true. Midi Health and Science&Humans both sit comfortably inside categories femtech has funded for years. What's different is the specificity of the newer bets: continuous monitoring, wearables, real-time hormone data. That's a narrower, newer thesis than "menopause telehealth," and it's the part of the category actually pulling in fresh capital and new investors like Khosla, rather than just femtech-dedicated funds recycling their thesis.
Where this fails as a takeaway
The comparison breaks down if you're a beauty founder looking at this as evidence you should pivot to diagnostics. You shouldn't, unless you actually have a hardware or clinical data product to build. The monitoring startups raising $10M to $50M rounds are selling to a different investor thesis, one built on recurring data and acquisition by health systems, not one built on gross margin and retail velocity. A skincare brand chasing a wearable-style valuation multiple will find out fast that beauty investors and health-tech investors are not pricing the same risk.
It also fails if you read "out-raised" as "will out-earn." Hormone health startups are earlier, smaller, and burning capital to build categories that don't fully exist as consumer habits yet. Beauty is a $108B industry with actual revenue behind it today. The founders who benefit from the "hormone health is booming" framing are the ones currently raising in it, and the investors who benefit are the ones who got in at Clair Health's or Science&Humans' valuation before the later-stage funds Ida Tin says don't exist yet finally show up.
The decision this leaves for anyone allocating capital or attention: hormone health is where the marginal dollar is moving with unusual density right now, six deals doing what took skincare years to raise. Beauty is where the money already lives. Betting on the first requires believing continuous monitoring becomes a habit within the next decade. Betting on the second requires believing nothing has to change at all.
